For example, unlike in human breast cancers, the clinical benefits of Her2 amplifications and their association with Her2 overexpression are not straightforward in CMTs9,10, putting into question the incidence and potential clinical utility of ERBB2 amplification in CMTs. Here, ERBB2 is linked to breast carcinoma.